Received: 14 February 2022
Accepted: 12 May 2022
First Online: 13 June 2022
Change Date: 28 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/S40463-022-00589-3
: Institutional ethics review necessity was inquired from McMaster University’s institutional Hamilton Integrated Research Ethics Board (HiREB), and determined to not be required for this study.
: Not applicable.
: No conflicts of interest related to this study.
: DD Sommer: GlaxoSmithKline, Sanofi: principal investigator, advisory board; Medtronic: speaker. KA Smith: advisory board fees from Sanofi, speaker fees from Mylan. MA Tewfik: Sanofi: principal investigator and consultant; AstraZeneca: principal investigator and consultant; Stryker: consultant and speaker; Novartis: consultant and speaker; Pentax: consultant; GSK: consultant; Mylan: speaker; Thieme: royalties. A Thamboo: Storz consultant; Medtronic speaker honorarium; Stryker consultant; Sanofi advisory board; GSK speaker honorarium.